Add BrightSurf on Google Email

Science News for May 30, 2026


New AI approach aims to predict radiation dose before therapy in advanced prostate cancer

A new machine-learning model uses pre-therapy PET/CT scans to estimate radiation dose to tumors and healthy organs, improving patient selection and reducing toxicity risk. The study's findings suggest a promising ability to predict post-therapy dosimetry, which may optimize treatment plans for individual patients.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMay 30, 2026

Cancer diagnostic delay rates associated with a population-based screening trial evaluating a cell-free DNA multicancer early detection test

A population-based screening trial evaluating a cell-free DNA multicancer early detection test found modest increases in diagnostic delay rates for head and neck, lung, and upper gastrointestinal cancers. These findings suggest that future trials may need to consider system-level spillover effects on healthcare resources.

SourceJAMA Network·JournalJAMA·DateMay 30, 2026

Immigration ban and the US health care workforce

A recent immigration ban could reduce the US physician and nurse workforce, exacerbating health care workforce shortages in already underserved communities. The study found nearly 24,000 physicians and 56,000 nurses from banned countries contributed to the US healthcare workforce in 2023.

SourceJAMA Network·JournalJAMA Network Open·DateMay 30, 2026

Ethanol extracts of justicia carnea leaves mitigate pancreatic oxidative stress and preserve islet glucagon expression in TNBS-treated mice

This study found that Justicia carnea ethanol extracts effectively reduced oxidative stress markers, inflammation, and lipid peroxidation in a mouse model of chronic pancreatitis. The extracts also preserved islet glucagon expression, indicating potential therapeutic benefits for pancreatic damage.

SourceXia & He Publishing Inc.·JournalJournal of Exploratory Research in Pharmacology·DateMay 30, 2026

A peptide-targeted, hypoxia-responsive adeno-associated virus platform for tumor-selective delivery of chemokines and PNAi in non-small cell lung cancer

This AAV platform integrates MGS4 peptide-guided capsid targeting, hypoxia-responsive elements, and dual shRNA vectors to selectively deliver chemokines and PNAi to NSCLC tumors. The combination of these elements aims to enhance antitumor immunity while suppressing tumor invasiveness.

SourceXia & He Publishing Inc.·JournalExploratory Research and Hypothesis in Medicine·DateMay 30, 2026

ASCO: Tile-based radiation therapy lowers risk of recurrence in brain metastases

A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...

SourceUniversity of Texas M. D. Anderson Cancer Center·TypeRandomized controlled/clinical trial·DateMay 30, 2026